RIVILY Trademark
Trademark Overview
On Monday, November 17, 2025, a trademark application was filed for RIVILY with the United States Patent and Trademark Office. The USPTO has given the RIVILY trademark a serial number of 99500953. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Wednesday, June 10, 2026. This trademark is owned by Axsome Therapeutics, Inc.. The RIVILY trademark is filed in the Pharmaceutical Products category with the following description:
Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss
General Information
| Serial Number | 99500953 |
| Word Mark | RIVILY |
| Filing Date | Monday, November 17, 2025 |
| Status | 730 - FIRST EXTENSION - GRANTED |
| Status Date | Wednesday, June 10, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, February 10, 2026 |
Trademark Statements
| Goods and Services | Medicated and pharmaceutical preparations for use in connection with humans, namely, antibiotics, antifungals preparations, antivirals, and for treatment of cardiovascular, dermatological, respiratory, central nervous system, gastro-intestinal diseases, autoimmune, metabolic, endocrine, musculo-skeletal, genitourinary, tissue and organ, ocular, ophthalmological, immune system, pain, kidney, urological, and bone diseases and disorders and for the treatment of fibromyalgia, smoking cessation, narcolepsy, excessive daytime sleepiness, alzheimer's disease agitation, migraine, diabetes, hypertension, skin disorders, allergies, asthma, obesity, and hair loss |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Monday, November 17, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Axsome Therapeutics, Inc. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10007
US |
| Party Name | Axsome Therapeutics, Inc. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 03 - Corporation |
| Address | New York, NY 10007
US |
Trademark Events
| Event Date | Event Description |
| Monday, November 17, 2025 | NEW APPLICATION ENTERED |
| Monday, November 17, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Monday, November 17, 2025 | APPLICATION FILING RECEIPT MAILED |
| Friday, January 16, 2026 | ASSIGNED TO EXAMINER |
| Monday, January 19, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, February 4, 2026 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, February 10, 2026 | PUBLISHED FOR OPPOSITION |
| Tuesday, February 10, 2026 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, April 7, 2026 | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Wednesday, June 10, 2026 | SOU TEAS EXTENSION RECEIVED |
| Wednesday, June 10, 2026 | SOU EXTENSION 1 FILED |
| Wednesday, June 10, 2026 | SOU EXTENSION 1 GRANTED |
| Thursday, June 11, 2026 | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
